Contraindications to receiving VAXNEUVANCE (PCV15) vaccine documented in Merck’s package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PCV15 or any vaccine containing diphtheria toxoid.
Data on the administration of PCV15 to women who are pregnant is insufficient for Merck pharmaceuticals to provide any information on the risks of vaccination during pregnancy. There is no available data on the effects of PCV15 on the breast-fed infant and it is recommended that breastfeeding women carefully consider the possible risk of vaccination on the infant when considering this vaccine.
PCV15 is approved for individuals six weeks of age and older. Individuals under the age of six weeks should not receive PCV15.
